Table 1.
Baseline demographics and clinical characteristics of matched patients in the CC and SC
| CC (n=605)
|
SC (n=92)
|
|||
|---|---|---|---|---|
| n/mean | %/SD | n/mean | %/SD | |
| Age, years (mean) | 41.1 | 10.3 | 42.5 | 11.8 |
|
| ||||
| Age group, years | ||||
|
| ||||
| 18–30 | 98 | 16.2% | 16 | 17.4% |
| 31–64 | 499 | 82.5% | 72 | 78.3% |
| ≥65 | 8 | 1.3% | 4 | 4.3% |
|
| ||||
| Sex | ||||
|
| ||||
| Male | 296 | 48.9% | 44 | 47.8% |
| Female | 309 | 51.1% | 48 | 52.2% |
|
| ||||
| Geographic region | ||||
|
| ||||
| East Anatolia | 19 | 3.1% | 1 | 1.1% |
| Southeastern Anatolia | 47 | 7.8% | 10 | 10.9% |
| Marmara | 257 | 42.5% | 12 | 13.0% |
| Aegean | 35 | 5.8% | 9 | 9.8% |
| Mediterranean | 78 | 12.9% | 19 | 20.7% |
| Black Sea | 55 | 9.1% | 1 | 1.1% |
| Central Anatolia | 114 | 18.8% | 40 | 43.5% |
|
| ||||
| Baseline Comorbidity Index ≥5% | ||||
|
| ||||
| CCI score | 1.3 | 1.0 | 1.2 | 0.9 |
|
| ||||
| Individual comorbidities | ||||
|
| ||||
| COPD | 98 | 16.2% | 15 | 16.3% |
| Connective tissue disease (without RA) | 79 | 13.1% | 3 | 3.3% |
| Ulcer | 137 | 22.6% | 14 | 15.2% |
| Diabetes mellitus (type 1 and 2) | 39 | 6.4% | 6 | 6.5% |
| Mild liver disease | 32 | 5.3% | 7 | 7.6% |
| Hypertension | 109 | 18.0% | 14 | 15.2% |
| Depression | 55 | 9.1% | 9 | 9.8% |
|
| ||||
| Concomitant disease | ||||
|
| ||||
| PsA or PsO | 90 | 14.9% | 11 | 12.0% |
| Crohn’s disease | 52 | 8.6% | 5 | 5.4% |
| AS | 374 | 61.8% | 61 | 66.3% |
| Ulcerative colitis | 47 | 7.8% | 7 | 7.6% |
|
| ||||
| Baseline RA-related therapies and DMARDs | ||||
|
| ||||
| Hydroxychloroquine | 63 | 10.4% | 7 | 7.6% |
| Sulfasalazine | 127 | 21.0% | 27 | 29.3% |
| Azathioprine | 82 | 13.6% | 5 | 5.4% |
| Cyclophosphamide | 6 | 1.0% | 0 | 0.0% |
| Leflunomide | 63 | 10.4% | 10 | 10.9% |
| Methotrexate/methotrexate sodium | 167 | 27.6% | 29 | 31.5% |
| NSAIDs | 521 | 86.1% | 84 | 91.3% |
| Corticosteroids | 464 | 76.7% | 76 | 82.6% |
|
| ||||
| Duration of baseline IFX use | ||||
|
| ||||
| Days (mean) | 422.3 | 329.6 | 437.6 | 336.1 |
Abbreviations: AS, ankylosing spondylitis; CC, continuers cohort; CCI, Charlson Comorbidity Index; DMARDs, disease-modifying antirheumatic drugs; IFX, infliximab; NSAIDs, nonsteroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SC, switchers cohort.